EGFR and glioblastoma: In our clinical pipeline, a molecularly engineered recombinant anti-CD3 x anti-EGFR BiAb (rEGFRBi) with deletion of the sequence responsible for allergic reactions, has markedly enhanced cytotoxicity, and induced Th1 cytokine secretion when engaging multiple EGFR + tumor cell lines including GBM [32].